{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Simeoli R"],"funding":["Italian Ministry of Health","Italian Ministry of Health with \"Current Research funds.\""],"pagination":["872"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11280286"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(7)"],"pubmed_abstract":["Eosinophilic oesophagitis is a long-term complication of oesophageal atresia (EA), an uncommon condition that affects approximately 1 in 3500 infants. An exploratory, open-label phase 2 clinical trial was conducted in paediatric eosinophilic oesophagitis after oesophageal atresia (EoE-EA) to assess the safety, pharmacokinetics, and efficacy of oral viscous budesonide (OVB). In total, eight patients were enrolled in the study and assigned to a twice-daily dosing regimen of either 0.8 or 1 mg OVB, depending on age and height, administered for 12 weeks. OVB was safe and effective in the treatment of EoE-EA. The current investigation focuses on the pharmacokinetics of budesonide and the impact of an oral viscous formulation on its absorption and bioavailability. Using a non-linear mixed effect"],"journal":["Pharmaceutics"],"pubmed_title":["Pharmacokinetic Evaluation of Oral Viscous Budesonide in Paediatric Patients with Eosinophilic Oesophagitis in Repaired Oesophageal Atresia."],"pmcid":["PMC11280286"],"funding_grant_id":["RC2019.1.6_ROSSI"],"pubmed_authors":["Lava SAG","De Angelis P","Rea F","Dionisi Vici C","Simeoli R","Roversi M","Rossi P","Goffredo BM","Simonetti A","Malamisura M","Angelino G","Di Deo A","Biondi I","Cairoli S","Tambucci R","Della Pasqua O","Pontrelli G"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetic Evaluation of Oral Viscous Budesonide in Paediatric Patients with Eosinophilic Oesophagitis in Repaired Oesophageal Atresia.","description":"Eosinophilic oesophagitis is a long-term complication of oesophageal atresia (EA), an uncommon condition that affects approximately 1 in 3500 infants. An exploratory, open-label phase 2 clinical trial was conducted in paediatric eosinophilic oesophagitis after oesophageal atresia (EoE-EA) to assess the safety, pharmacokinetics, and efficacy of oral viscous budesonide (OVB). In total, eight patients were enrolled in the study and assigned to a twice-daily dosing regimen of either 0.8 or 1 mg OVB, depending on age and height, administered for 12 weeks. OVB was safe and effective in the treatment of EoE-EA. The current investigation focuses on the pharmacokinetics of budesonide and the impact of an oral viscous formulation on its absorption and bioavailability. Using a non-linear mixed effect","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-05-22T03:11:03.918Z","creation":"2025-04-19T13:12:22.146Z"},"accession":"S-EPMC11280286","cross_references":{"pubmed":["39065569"],"doi":["10.3390/pharmaceutics16070872"]}}